Search
Itraconazole
go.drugbank.com/drugs/DB01167ApprovedInvestigationalFirst synthesized in the early 1980s, itraconazole is a broad-spectrum triazole antifungal agent used to treat a variety of infections. … [A34257] It is a 1:1:1:1 racemic mixture of four diastereomers, made up of two enantiomeric pairs, each possessing three chiral centers.
Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseProducts: ITRACONAZOL AL 100MG HART, ITRACONAZOL 1A PHARM 100MGGadopentetic acid
go.drugbank.com/drugs/DB00789ApprovedInvestigationalA complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs.
Categories: Compounds used in a research, industrial, or household settingProducts: Magnevist 2 mmol/l - InjektionslösungYttrium Y-90
go.drugbank.com/drugs/DB13076ApprovedInvestigationalYttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer.
Fosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalFosnetupitant is the pro-drug form of netupitant [FDA label]. … ) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting [L2631].
Atracurium besylate
go.drugbank.com/drugs/DB00732ApprovedA non-depolarizing neuromuscular blocking agent with short duration of action. … Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents
Products: Atracurium - (for Single Dose ), Atracurium Kabi 10mg/ml Solution for Injection USPRESP301
go.drugbank.com/drugs/DB16497InvestigationalAdditionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary … RESP301 was also studied in a terminated trial (NCT05101915) for patients with mycobacterium abscesses and cystic fibrosis and in a completed trial with results (NCT04460183) for efficacy and safety in
Categories: Experimental Unapproved Treatments for COVID-19Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalDeucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered
Dronabinol
go.drugbank.com/drugs/DB00470ApprovedIllicitInvestigationalFrom a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. … If not provided in their activated form (such as through synthetic forms like Dronabinol or [DB00486]), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A
Synonyms: 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol, 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-olCMC 001
go.drugbank.com/drugs/DB05353InvestigationalCMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Pamidronic acid
go.drugbank.com/drugs/DB00282ApprovedInvestigationalPamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977.
Categories: Drugs for Treatment of Bone DiseasesProducts: Pamidronate Disodium for Injection, MENEDRON-L 15 MG IV ENJEKSİYONLUK LİYOFİLİZE TOZ İÇEREN FLAKON (4 FLAKON)